Biocon Share Price in Focus; Subsidiary Secures U.S. FDA Nod for Liraglutide Injection for Type 2 Diabetes

Biocon Limited announced that its wholly owned subsidiary Biocon Pharma Limited has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Liraglutide Injection (gVictoza®). The approval relates to the 18 mg/3 mL (6 mg/mL) formulation available in single-patient-use prefilled pens. 

Treatment Indication and Usage 

Liraglutide is prescribed for the treatment of Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above whose blood sugar levels are not adequately controlled. The therapy is typically used alongside diet and exercise as part of a broader diabetes management programme. 

Expansion of Biocon’s Diabetes Portfolio 

The approval comes shortly after the company secured approval for another Liraglutide-based product (gSaxenda®) on February 24, 2026. The latest clearance strengthens Biocon’s range of complex, vertically integrated pharmaceutical products, particularly in the metabolic and diabetes therapy segment. 

About Biocon 

Biocon Limited is a global biopharmaceutical company headquartered in Bengaluru, India. The company focuses on the development and manufacturing of biosimilars, generic formulations and complex biologics across therapeutic areas such as diabetes, oncology and immunology. Through its subsidiaries and global partnerships, Biocon supplies medicines to multiple international markets. 

Read More: Gravita India Share Price in Focus; To Acquire Rashtriya Metal Industries for ₹559 Crore! 

Biocon Share Price Performance  

As of 13 March 2026, at 11:18 AM, Biocon Limited share price is trading at ₹384.35 per share, reflecting a decline of 2.0% from the previous closing price. Over the past month, the stock has gained by 1.69%. 

Conclusion 

The approval of Liraglutide Injection expands Biocon’s diabetes treatment portfolio and strengthens its presence in global pharmaceutical markets. It also reflects the company’s continued focus on developing therapies in the metabolic and diabetes treatment segment. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.